420 with CNW — Study Suggests Marijuana Users Are Less Predisposed to Type 2 Diabetes

A recently released analysis has found a link between a history of cannabis usage and a decreased incidence of type 2 diabetes in adulthood. The analysis was done on seven studies, which include four cohorts and 11 surveys, by researchers at Iran’s Tabriz University of Medical Sciences. Compiling the findings, NORML stated that the four cohorts combined totaled more than 478,000 participants.

The comprehensive analysis revealed that the chances of developing type 2 diabetes in those who had been exposed to marijuana were diminished by a factor of 0.48 compared to those without any marijuana exposure.

The researchers highlighted that the act of consuming cannabis could potentially confer a safeguarding impact on the likelihood of type 2 diabetes development. However, they appended that due to the notable variation in findings across studies, it would be prudent to encourage investigations of heightened credibility, given the surge in marijuana consumption and legalization.

The researchers elaborated, saying “to the best of our knowledge, our analysis constitutes the most current body of evidence concerning the connection between T2DM and marijuana use,” as cited by NORML. They continued: “Given the increasing popularity of marijuana usage and the legalization thereof, there exists a growing imperative to design prospective, long-term, randomized studies that delve into the genuine ramifications of marijuana consumption and furnish pragmatic guidelines for its management.”

Commonly referred to as adult-onset diabetes and type 2 diabetes mellitus, type 2 diabetes is a chronic ailment characterized by elevated blood sugar levels. This form of diabetes is more prevalent than type 1, and, as Harvard Medical School states, although it typically manifests in middle and later life, it is progressively affecting younger demographics.

The Centers for Disease Control and Prevention (CDC) report that more than 37 million Americans have diabetes, with type 2 diabetes comprising 90% to 95% of these cases. The CDC further noted that “insulin, a hormone manufactured by the pancreas, functions akin to a key, enabling blood sugar to enter the body’s cells and be utilized as energy. However, in cases of type 2 diabetes, cells exhibit an abnormal response to insulin, a phenomenon known as insulin resistance.”

The CDC further clarified: “The pancreas compensates by generating more insulin in an attempt to provoke a cellular response. With time, the pancreas becomes overwhelmed, leading to escalated blood sugar levels, consequently setting the stage for prediabetes and eventually type 2 diabetes.”

In 2020, a study examined the potential of marijuana to reduce diabetes risk in individuals with hepatitis C. The study’s authors reported that “HCV infection heightens the risk of insulin resistance, consequently increasing susceptibility to diabetes. In the general populace, indications suggest that marijuana usage might offer protective effects against diabetes and related disorders.”

Furthermore, NORML highlighted that previous observational inquiries uncovered an inverse relationship between marijuana use and the odds of adult-onset diabetes and obesity. In clinical trial settings, it was revealed that administering THCV improved glycemic control in type 2 diabetes cases.

The researchers added that a placebo-controlled trial, documented in February, reported substantial enhancements in cholesterol and blood sugar levels among diabetic subjects who consumed plant-derived cannabinoid extracts via an eight-week regimen of two daily CBD sublingual spray doses.

There are other medicinal attributes of marijuana which companies such as IGC Pharma Inc. (NYSE American: IGC) are looking to leverage in order to come up with FDA-approved formulations aimed at treating several conditions, including chronic pain.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Suggests Marijuana Users Are Less Predisposed to Type 2 Diabetes

The comprehensive analysis revealed that the chances of developing type 2 diabetes in those who had been exposed to…

420 with CNW — AMA Study Finds Marijuana Smoking Viewed as Safer Than Cigarette Smoking

According to a recent AMA study, people are beginning to perceive marijuana smoking or being around marijuana smoke as being less harmful than smoking or being around tobacco smoke. Researchers asked 5,035 American adults three times — in 2021, 2020 and 2017 — about their opinions of the hazards associated with both substances. They discovered a significant change over time, with more participants saying they thought marijuana smoke was typically safer than tobacco smoke.

Published in the “Journal of the American Medical Association” (JAMA) Substance Use and Addiction, the survey asked respondents whether they believed that smoking one joint of marijuana daily was significantly less safe than smoking one cigarette daily, significantly less safe, about the same amount of safety or much safer. The study authors noted that people believed using marijuana regularly to be safer than using tobacco. Moreover, this perception became progressively more favorable toward marijuana as the years went by.

For instance, 33.7% of respondents in 2017 indicated that smoking cannabis once a day was either substantially or slightly riskier than smoking a cigarette, compared to 36.6% who believed cannabis was safer. About 30% claimed that they posed similar hazards. Only 25.5% of people still held this belief in 2021, whereas 44.3% of people, a 21% rise from 2017, thought cannabis was less risky than cigarettes.

Similar patterns were seen when respondents were questioned about the relative risks of being exposed to cigarette and cannabis smoke. In 2017, 35.1% of respondents believed that exposure to cigarette smoke was more hazardous than exposure to secondhand marijuana smoking, while 29.2% disagreed. Another 35.6 percent disagreed, claiming that neither was less risky nor safer. In 2021, four years later, 25.5% of respondents claimed that marijuana smoke in close proximity to others was worse than cigarette smoke, while 40.1% disagreed.

Participants were also asked to rank the relative safety of tobacco smoke and marijuana smoke for various demographics. Among adults, 12.6% thought cannabis was mostly or entirely safe, compared to 2.4% who thought the same about tobacco. Compared to cigarettes, which had a response of 1.8%, cannabis had a response of 4.8% that it was entirely or somewhat safe for youngsters. And compared to cigarettes, cannabis smoke was deemed to be usually safe for pregnant women by 5.3% of respondents, versus 1.4% for cigarettes.

The authors noted that the legalization of cannabis in the participant’s state of residence was not a standalone predictor of change over time. This shows that the rising view of marijuana safety may be a more widespread, nationwide trend rather than a trend limited to places where cannabis use is allowed.

This finding appears to partially conflict with the authors’ prediction that if more states legalize cannabis, risk perception may decline even further, which may be related to increased cannabis intake and exposure to secondhand marijuana smoke.

The authors express concern about the shift in public perceptions regarding marijuana’s relative safety and suggest that public health initiatives may be required to inform the public about potential risks and stop the rising social acceptance of marijuana smoke exposure.

This new study’s release coincides with a recent Gallup poll revealing that almost one-half of Americans have tried marijuana and that more individuals currently smoke marijuana than tobacco cigarettes. The majority also expresses no particular concern about the consequences of adult marijuana use.

Given that many people use marijuana for medicinal purposes, one way to reduce any possible harms from smoking the substance is by switching to any FDA-approved cannabis medicines that manufacturers such as IGC Pharma Inc. (NYSE American: IGC) offer to address chronic pain and other symptoms.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — LA Mayor to Announce Head of City Marijuana Agency

Los Angles Mayor Karen Bass is expected to announce a new official to head the city’s marijuana regulatory agency. Bass is changing leadership in a myriad of city agencies and recently listed the position of executive director of Los Angeles’ Department of Cannabis Regulation (DCR) on the city employment site.

Interested candidates have until 4 p.m. on Aug. 18, 2023, to submit their applications for the DCR executive director position. With an annual salary of $155,681 to $276,075, the DCR executive director will oversee an agency of 55 employees and a recreational cannabis market that sells roughly $1 billion worth of cannabis products every year, a feat that equals states with older adult-use cannabis markets.

The California Department of Tax and Fee Administration states that Los Angeles’ recreational marijuana program generated $236,871,994 in taxable revenue during the first quarter of the year. With California being home to what is arguably the largest marijuana market in the world, it’s no surprise that the state’s most populous city has an adult-use market that rivals established markets in entire states.

Experts predict that California will see close to $5.9 billion in medical and recreational cannabis sales this year followed by Michigan with an estimated combined sales of $3.1 billion. Although LA hasn’t officially stated whether current DCR executive director Michelle Garakian will step down, the listing on the city’s employment website has raised speculation that she is on her way out.

Officials did not respond to inquiries on the executive director’s future with the cannabis agency and the currently-open director position. Garakian was a former aide to Los Angeles’ previous mayor Eric Garcetti and accepted the position of DCR’s executive director in March 2022, replacing Cat Packer who was instrumental in the issuance of more than 1,200 cannabis-related licenses.

She inherited a cannabis industry mired in bureaucracy, red tape and delays amid claims that the regulatory agency had been given an almost impossible task and complaints from cannabis business owners.

As the interim executive director, Garakian planned on boosting communications with applicants and operators while eliminating the bureaucratic red tape that caused major delays and encouraged the growth of the illicit cannabis market. Shortly after taking the position, Agrarian said in an interview that the regulatory agency had also changed verification protocols for social-equity applicants.

These changes included using police reporting districts to prove residency, the presence of a cannabis-related conviction, or living in an area that was disproportionately affected by the war on drugs.

The surging sales of marijuana have created opportunities for enterprises such as IGC Pharma Inc. (NYSE American: IGC) to start taking cannabis drug products through the clinical development process so that patients can access those medicines through the conventional medical system as products gain FDA approval.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Gallup Poll Finds Highest Ever Support for Cannabis Legalization Among Republicans

A recent examination of survey data from Gallup shows that Republican backing for cannabis legalization has reached an unprecedented peak on a nationwide scale. However, a deepening partisan schism has emerged over the last couple of decades, with Democrats having swiftly and more openly embraced this cause. Most Democrats and Independents leaning toward the Democratic Party (amounting to 83%) and also Republicans and Independents with an inclination toward the GOP (accounting for 55%) are in favor of dismantling the ban on cannabis.

These insights, extracted from Gallup’s 2022 survey data, illustrate a disparity of 28% in opinion on the matter of cannabis reform between these political factions. The divergence is now broader compared to the scenario two decades ago when backing from both sides was less than 50%.

According to the most recent research, Democrats have demonstrated a more positive attitude toward marijuana legalization than Republicans since 2003. The data continues by revealing that between 2013 and 2022, there was a synchronized increase in the number of each political party’s supporters of legalizing marijuana. However, Democratic group growth has exceeded Republican faction growth. This has caused the political gap on this matter to be slightly more apparent in the most recent measuring year compared to two decades ago.

Marijuana legalization is one of nine issues out of the 24 analyzed by Gallup, where both political parties are typically in agreement with the majority opposition or support at different levels. The closest comparison to the marijuana debate is same-sex marriage, with a 28%-point political margin; it is supported by 57% of Republicans and 85% of Democrats.

“Political polarization continues to be a critically important feature of the American political landscape,” the report states. “On all 24 of the subjects examined in this analysis, there are now major — and in some cases, enormous — partisan disparities in opinion. This affirms the essential tenet of any American political analysis, which holds that people’s political identities are strongly connected with their opinions on policy and social problems giving rise to significant variations in those opinions among political segments.”

A number of other analyses issued this year support the idea that a majority of Americans, regardless of party affiliation, are willing to reform federal cannabis laws. However, while the majority of states have approved some kind of medical marijuana and 23 states have already passed legislation legalizing cannabis for recreational use, efforts to adopt federal changes have lagged well behind public sentiment.

This lag between public sentiment and actions in Congress suggest that it may take a while for federal marijuana policy to be overhauled. Despite this gloomy possibility, companies such as IGC Pharma Inc. (NYSE American: IGC) are on course to thrive as sellers of federally approved cannabis-based treatments if their R&D programs yield successful outcomes.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Cannabis Industry Lobbying Increases as Looming Government Shutdown Leaves SAFE Banking in Balance

The U.S. marijuana sector persists in allocating substantial financial resources toward influential advocates, aiming to sway senators into endorsing marijuana reform. Nonetheless, this endeavor faces a potential impediment in the form of an imminent government shutdown, capable of profoundly disrupting the legislative schedule of Congress.

During the first six months of 2023, marijuana enterprises and industry coalitions invested more than $2.4 million in lobbying efforts directed at the Senate, according to the latest disclosures in federal lobbying records. This falls short of the $2.9 million expended during the latter half of 2022, including the session following the general election, when the prospects of marijuana banking reform appeared remarkably promising.

While certain corporations have trimmed their expenses or completely revoked contracts due to economic challenges facing the sector, other entities have come to terms with the reality that lobbying expenditures are an essential investment for their survival.

However, the outcomes of those efforts so far bear a frustrating resemblance to the past: well-received and long-anticipated reforms, such as guaranteed access to banking services and more ambitious objectives such as rescheduling, persist as tantalizingly close yet unattainable. As lawmakers disperse for the August recess, the possibility of the SAFE Banking Act being ratified within President Joe Biden’s inaugural term remains viable, albeit subject to change.

Yet, the likelihood of success will gradually diminish without the passage of critical spending bills, as indicated by congressional staff members and lobbyists on Capitol Hill.

Following the resumption of sessions on Sept. 5, 2023, Congress’s principal focus will be on ratifying the essential spending legislation to prevent a government shutdown on Oct. 1. A government shutdown is set off when Congress fails to pass the necessary funding bills, resulting in substantial disruption, a scenario that is currently foreseeable, as recently pointed out by the Brookings Institution, a think tank situated in Washington, DC.

As the interval without a spending debate increases, the time allocated on legislative calendars for other legislative actions decreases. This encompasses the consideration of the SAFE Banking Bill, which is slated to undergo a comprehensive markup hearing in the Senate Banking Committee, a precursor to the final Senate floor vote. The procedure advocated for this year experienced a major milestone when the bill obtained an informational hearing in mid-May.

However, a markup hearing, a session involving the introduction and debate of amendments to potentially modify the bill, was initially promised for the summer months, first in June and then in July. However, disagreements between bipartisan representatives regarding the final form of the bill, coupled with the aim of securing additional Republican endorsements to ensure the bill’s passage, prompted the Senate to adjourn for the August recess without holding this hearing. Additionally, complications have arisen from requests by companies that have existing bank accounts.

Nonetheless, observers in Washington broadly concur that significant hurdles persist for this proposal, primarily concerning antimoney laundering provisions and the ability to garner adequate Republican support to ensure passage in the full Senate. Lobbying records substantiate the evidence: while rescheduling and the potential establishment of a nationwide legalized marijuana industry akin to Canada’s aspirations endure as long-term goals, the SAFE Banking Bill remains the paramount priority of the marijuana sector.

For some companies that have chosen a pharmaceutical path to cannabis product development, such as IGC Pharma Inc. (NYSE American: IGC), access to banking services isn’t an issue because they engage in a federally accepted business, unlike mainstream marijuana companies which are only state approved.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — CNN’s Dr. Gupta Discusses Marijuana Use by Seniors

In a recent article titled “Cannabis is Having a Senior Moment,” CNN’s Dr. Sanjay Gupta talked about the increasing rates of marijuana use among older Americans. People aged 65 and older are now the fastest growing group of marijuana users in the country, Gupta said, dubbing the trend a kind of “senior moment” that has left him quite surprised.

America is currently home to a massive state-level medical marijuana industry that serves millions of patients and generates hundreds of millions of dollars per year in medical cannabis sales. Surprisingly, a significant portion of medical marijuana patients are older individuals, belying the idea that cannabis in all its forms is a young man’s game.

Unlike younger, more liberal generations who grew up after the war on drugs, seniors spent their formative years in a world that criminalized cannabis as harshly as cocaine and heroin. They experienced anticannabis sentiment for the majority of their lives and were inundated with messages about the personal and societal ails associated with consuming cannabis.

This generation is now adopting cannabis in surprising numbers, Gupta said, with recent studies indicating that more seniors are using cannabis to address age-related issues such as pain from arthritis and poor sleep. In many cases, seniors prefer to use cannabis in place of prescription opioids, antidepressants and sleeping pills, Gupta noted.

The growing trend of cannabis use among America’s senior population encouraged Gupta to begin working on his most recent documentary, “Weed 7: A Senior Moment.” Gupta notes that cannabis could have “tremendous implications” if it could replace the pharmaceuticals many American seniors take on an almost-daily basis. Prescription pharmaceuticals have a myriad of side effects that can significantly diminish the quality of life of seniors while cannabis doesn’t seem to exhibit severe side effects.

Incorporating cannabis into treatments for seniors could also result in major cost savings as the United States spends close to $600 billion of its annual healthcare budget on pharmaceuticals alone.

With Gupta estimating that more than 30% of seniors take at least five pharmaceuticals per day, overall prescription pharmaceutical medication use may decrease if seniors transition to using cannabis as an alternative medication in mass.

Close to 40 states currently allow their residents to use medical marijuana to address more than 20 medical conditions. These conditions include chronic pain, inflammatory bowel disease, irritable bowel syndrome, obsessive-compulsive disorder and PTSD, to name a few.

This medical use of marijuana lends credence to the efforts by companies such as IGC Pharma Inc. (NYSE American: IGC) to develop FDA-approved formulations from cannabis targeting different disease conditions, such as chronic pain.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW— Study Finds Workplace Accident Rates No Different Between Off-Duty Marijuana Users and Non-Users

Employees who engage in off-duty marijuana consumption do not display a higher likelihood of encountering workplace injuries when compared to abstainers, according to recent research that challenges the sweeping zero-tolerance policies commonly adopted by employers. On the other hand, individuals who use marijuana during work hours exhibit a nearly twofold increase in the probability of being involved in a workplace incident, in contrast to both nonusers and those who consume marijuana during their personal time.

This discovery stems from a collaborative effort by researchers hailing from the Toronto Rehabilitation Institute, the University at Buffalo and the University of Toronto. The findings were recently published in the “Canadian Journal of Public Health.”

In two years, the study tracked 2,746 Canadian workers who occupied positions spanning both safety- and nonsafety-sensitive roles. The exhaustive analysis paid specific attention to the 11.3% subset of the sample who sustained workplace injuries during the specified timeframe.

Among the diverse pool of respondents, the investigation highlighted that 10.2% of those affected by workplace injuries were classified as nonusers, with 11.14% identified as off-duty consumers. Meanwhile, a notable 20.13% reported marijuana consumption either within two hours before or during their working hours.

According to study findings, individuals who admitted to using marijuana within the confines of their workplace exhibited a 1.97 times greater risk of encountering workplace injuries in comparison to those who refrained from such consumption. Conversely, no significant association was observed between nonworkplace usage and the occurrence of workplace injuries.

Consequently, the researchers deduced that the critical factor influencing workplace injuries is the proximity of marijuana use to work hours rather than consumption outside of professional settings.

Stratifying the data for safety-sensitive workers revealed that injury rates stood at 20.14% for nonusers, 23.3% for off-duty consumers, and 31.35% for on-the-job indulgers. For nonsafety-sensitive roles, the figures were notably lower, with nonusers experiencing injury at a rate of 4.27%, off-duty users at 4.19%, and those consuming marijuana during work at a higher 12.3%.

The researchers affirmed that their study provides a more lucid perspective on the connection between marijuana use and workplace injuries, an area that previous conflicting studies have clouded. They explained that prior research had neglected the temporal aspect of consumption concerning workplace injuries, which their study effectively accounted for.

Ultimately, the researchers concluded that solely workplace-related marijuana use poses a genuine risk of future workplace injuries, regardless of whether the job role falls within the safety-sensitive category.

Some of the concerns about marijuana use will likely disappear as more enterprises bring to market cannabis-based formulations along the lines of what IGC Pharma Inc. (NYSE American: IGC) is developing for chronic pain management. These medications will move many medical marijuana users away from taking unprocessed cannabis, which is a source of concern for employers and some authorities.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Indoor MJ Growers Give Insights into How Preharvest Care Can Optimize Yields

The harvest phase is an essential step in making marijuana products such as flowers and oils. Before the crops are collected, a lot of careful planning and preparation happens. Different growers, whether they’re growing indoors, in greenhouses, or outdoors, need to learn different ways to do this. Each place has its own challenges.

For indoor growing, it’s important to have a clear plan and to be able to watch over the plants closely. Nic Robertson from 4Front Ventures says the company creates daily schedules for its plants leading up to harvest. This is when the plants finish their life cycle. Ryan Cook from Jushi Holdings agrees that planning and preparing well are keys to success in harvesting.

Although there are many ways to grow, there are some things that all successful growers do. They make sure the lighting is right, control the temperature and humidity, manage nutrients and take care of the leaves.

Indoor growers use special lights to help the plants grow. They start with lower-intensity light and gradually increase lighting as the plants develop. This helps the plants make more of the good stuff such as cannabinoids and terpenes, which make the plants valuable. They also use red light to improve the flavors and yields.

Temperature and humidity are important factors too. Growers adjust these to make sure the plants stay healthy and produce good yields. As plants get closer to harvest, the temperature and humidity are lowered to protect the valuable compounds and keep the plants safe from harmful things.

Nutrients the plants receive are carefully managed too. As the plants grow and start to produce buds, they need different nutrients. Nitrogen is decreased, while phosphorus and potassium are increased. This helps the plants make better buds and resin.

Watering the plants is like giving them a drink. But as harvest time approaches, watering changes. This helps the plants get rid of extra nutrients and prepare for harvest. It’s important to do this carefully so the flavor and smell of the final product stay good.

As the plants get closer to harvest, growers need to be very attentive. The plants need less water, so growers have to be careful not to overwater them. Some growers use special tools to measure how much moisture is in the plants’ growing medium. This helps them make the right decisions and keep the plants healthy.

In the end, everything comes down to balance. The right amount of light, the best temperature and humidity, the nutrients, and the water — everything needs to be just right. And as the time for harvest comes, growers carefully balance all these factors to make sure the plants are healthy and ready to become the products that people enjoy. It’s a mix of science and care, creating a special connection between humans and the plants they grow.

When the cultivation conditions are just right, upstream companies such as IGC Pharma Inc. (NYSE American: IGC) can obtain top-notch cannabis compounds to use in their efforts to develop standardized medicines that meet FDA requirements.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Bipartisan Senators in Pennsylvania File Bill Allowing Licensed Patients to Grow Medical Marijuana

A group of bipartisan senators in Pennsylvania have introduced a measure to expand Pennsylvania’s medical marijuana program by allowing patients aged 21 years and older to cultivate cannabis plants at home for personal use. The measure would allow registered medical marijuana patients in the state to grow up to six cannabis plants at home in a locked and enclosed location away from “ordinary public view.” Furthermore, it would grant medical cannabis dispensaries the right to sell cannabis seeds for home cultivation to registered patients.

Introduced by Senators Dan Laughlin and Sharif Street alongside half a dozen other senators, the bill does not seem to limit the total number of cannabis plants that could be cultivated in a home with more than one registered medical cannabis patient.

The measure has now been sent to the Senate Law and Justice Committee. Street and Laughlin said that since Pennsylvania legalized medical cannabis in 2016, the state’s medical cannabis program has ensured citizens across the Commonwealth can access lifesaving medicine. In a memo soliciting cosponsors for their medical cannabis home cultivation bill, the two senators wrote that while Pennsylvania’s MMJ industry has undoubtedly been beneficial, it is still inefficient in terms of access and cost.

They noted that records from the PA Department of Health show that some patients have to travel for more than two hours to access a medical cannabis dispensary, making the treatment unfeasible for a lot of Pennsylvanians. Furthermore, the senators wrote, medical cannabis patients in the state have long complained of the high costs of purchasing medical marijuana that make the treatment even more inaccessible.

The two stressed the importance of creating policies that “meet people where they are,” adding that legalizing home cultivation of medical cannabis would address the key issues of accessibility and cost that bog down Pennsylvania’s medical marijuana industry. It would also ensure that Pennsylvania residents have better means of meeting their health needs and are treated fairly and equitably under the state’s medical cannabis law.

As per the proposed measure, patients who cultivate more than the allowed number of cannabis plants or gift cannabis plants or products to other people may be liable to punishments, such as the loss of their home cultivation rights.

Laughlin and Street had introduced a recreational cannabis legalization bill last session, but it ultimately failed to advance. However, the two senators say the medical cannabis home cultivation bill is a significant improvement to the recreational cannabis bill, and they are optimistic about its chances of success.

With more people turning to medical marijuana to ease their symptoms in different jurisdictions, the marijuana-based formulations being developed by enterprises such as IGC Pharma Inc. (NYSE American: IGC) could have a large market to address, especially among those who want the medical benefits marijuana can bring minus running the associated risks, such as job losses due to positive drugs tests.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.